Roche won't sell diabetes business—it's looking for deals to boost it instead

Roche is looking for technology that could potentially shore up its diabetes care unit. The business has had a rough few years thanks to reimbursement pressure in the U.S.

A week after Johnson & Johnson said it was weighing “strategic options” for its diabetes device divisions, reports emerged that Roche was doing the same with its diabetes testing unit. But diagnostics chief Roland Diggelman put an end to speculation Wednesday, saying the Swiss company wants to expand the biz, Reuters reported.

Bloomberg reported Tuesday that “people familiar with the matter” said Roche was “considering options” for its diabetes care unit, including a spinoff or a sale.

Roche’s diabetes care sales dropped 4% in FY 2016, thanks to pricing pressure in the U.S. But Diggelmann dismissed reports the company was considering a sale, Reuters reported. In fact, he said, the company is on the prowl for new tech that could boost the flagging business.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"We basically have all of the technologies we need in-house in varying degrees of development, so we have to ask ourselves, 'How far are we along?'" Diggelmann said, as quoted by Reuters "We're looking around: Are there new possibilities, are there alternatives?"

Roche faced similar speculation in 2015, after Bayer sold off its diabetes device unit to KKR/Panasonic. But while Roche’s diabetes business had had a rough couple of years, thanks

To price cuts in the U.S., Diggelmann said at the time: "It's still a good business” and “a business with a future.”

The company markets the Accu-Chek line of devices, which includes blood glucose meters and insulin pumps. It leads the diabetes testing industry, ahead of competitors J&J, Abbott and KKR/Panasonic.

In May last year, Roche Diabetes Care inked a deal with Senseonics to sell the latter’s Eversense Continuous Glucose Monitoring System in Germany, Italy and the Netherlands. Senseonics’ system comprises a rice-sized sensor that is implanted just under the skin and measures blood glucose levels for 90 days.


Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.